Ju Dong Yang, MD
Comprehensive Transplant Center
8900 Beverly Blvd.
Los Angeles, CA 90048
Ju Dong Yang, MD
Hepatitis (A, B, C)
The research program of Ju Dong Yang, MD, has been focused on clinical and translational research of liver cancer. Dr. Yang conducted several population-based cohort studies to describe recent trends in liver cancer epidemiology in the United States. He published several outcome research papers in liver cancer. Dr. Yang has also conducted several modeling studies and proposed a survival prediction model in liver cancer patients. He has also conducted a multistate Markov model study and investigated the impact of liver cancer surveillance on overall survival in patients with cirrhosis. In addition, Dr. Yang has been interested in liver cancer health disparities research from a global perspective. His research highlighted that Africans have a very early onset of HCC with extremely poor survival. Finally, Dr. Yang has been interested in liver cancer biomarker research. He and his colleagues have reported that circulating tumor cells (CTC) are detectable in liver cancer patients and are independent predictors of patient survival. Our more recent study indicated that circulating cell-free tumor DNA mutation and methylation are promising diagnostic or prognostic biomarkers in liver cancer.
- Medical School: Sungkyunkwan University School of Medicine, 2005
- Master's: Mayo Clinic Rochester, 2011
- Residency: University of Arkansas for Medical Sciences, 2014
- Fellowship: Mayo Clinic Rochester, 2017
- Fellowship: Mayo Clinic Rochester, 2018
Awards & Activities
- Hans Popper Memorial Postdoctoral Research Fellowship Award, American Liver Foundation, 2016
- Clinic research award, American College of Gastroenterology, 2016
- Clinic research award, American College of Gastroenterology, 2017
- J. Arnold Bargen Award, Mayo Clinic, 2018
Click here for a list of peer-reviewed publications.
English / Korean